ABG Sundal Collier acted as Joint Global Coordinator and Joint Bookrunner in the NOK 286 million private placement in Nykode Therapeutics

On 27 August 2026, Nykode Therapeutics ASA (“Nykode”) announced the successful completion of a private placement, raising gross proceeds of NOK 286 million through the allocation of 65 million new shares at a subscription price of NOK 4.40 per share.

The private placement was multiple times oversubscribed with substantial interest from local and international investors.

The net proceeds from the private placement will be used to: (i) strengthen Nykode’s position for potential partnering by development of VB.10.NEO (including potential next-gen) and advancement of manufacturing enhancements, (ii) support accelerated transition of abi-suva from phase 2 to phase 3, (iii) explore expansion of abi-suva into locally advanced settings via a KOL-led Investigator Initiated Trial (IIT) targeting early-stage patient population recently validated by peer data, (iv) progress the Tolerance platform towards first clinical development by identifying a lead program within H1 2027, and (v) general corporate purposes.

ABG Sundal Collier acted as Joint Global Coordinator and Joint Bookrunner in the private placement. We congratulate Nykode on the successful private placement and would like to extend our gratitude for the vote of confidence.